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Abstract 
BACKGROUND: Around 15-25% of diabetes mellitus (DM) patients will develop diabetic foot ulcers (DFUs) with 
high morbidity, many studies have been proposed to search the most effective healing techniques.  
AIM: This study was conducted to demonstrate the ability of hyperbaric oxygen therapy (HBOT) as a 
complementary therapy in DFUs healing through raising vascular endothelial growth factor (VEGF) levels and 
suppressing tumour necrosis factor-alpha (TNF-α). 
METHODS: All patients received the same treatment including wound debridement and wound care, but the 
patients in the HBOT group, breathed 100% oxygen at 2.4 ATA for 90 minutes in total of 20 sessions (four 
weeks). 
RESULT: There were 32 diabetic patients with DFUs Wagner 3-4. VEGF levels after four weeks of HBOT was 
significantly elevated compared to the control group (p = 0.013). The effect size of VEGF levels was p = 0.005. 
TNF-α levels after four weeks of therapy were decreased (p = 0.01). Faster epithelialization is seen in the HBOT 
group (p < 0.001). We also performed path analysis, HBOT had a significant effect on the epithelialization (p < 
0.001) and VEGF levels affected the epithelialization process (p = 0.042). 
CONCLUSION: HBOT administration leads to increased VEGF levels, decreased TNF-α levels, and accelerated 
wound healing of DFUs patients. HBOT directly aids epithelialization and indirectly through VEGF upsurge and 
TNF-α downturn. 
 
 
 
Introduction 
 
Diabetes mellitus (DM) is a chronic disease 
caused by inadequate insulin production, or when 
insulin cannot be used effectively. This results in 
elevated blood sugar levels causing damage to the 
heart, blood vessels, eyes, kidneys, and nerves in 
longstanding uncontrolled DM [1], [2]. In patients with 
DM, the most common complications in blood vessels 
are macroangiopathy, neuropathy, immunosuppre-
ssion that facilitate inflammation, ischemia, infection, 
and cell death [2], [3]. These complications may lead 
to foot abnormalities such as a chronic ulcer, called 
diabetic foot ulcers (DFUs). 
An ulcer occurs because, at tissue damage or 
death, that associated with the degree of peripheral 
vascular disease in inferior limb and may be 
accompanied by infection [4], [5]. It is estimated 15-
25% of DM patients will develop DFUs with high 
morbidity, 40-80% will have high infection risk, and 
10-20% will require amputation [6]. 
The standard therapies of DFUs are to 
regulate normal blood sugar levels, antibiotics 
medication to prevent and treat infection, ulcer 
debridement, wound care, off-loading the affected 
limb, and to improve blood flow or revascularisation 
[2], [6], [7], [8], [9]. In addition to these standard 
therapies, there are many adjuvant therapies, such as 
hyperbaric oxygen therapy (HBOT), growth factor 
therapy, stem cells therapy [7], [10], autolytic 
debridement [4], and percutaneous transluminal 
angioplasty [11]. These modalities are also performed 
in the management of DFUs. Because of DFUs high 
morbidity risk, many studies have been proposed to 
search the most effective healing techniques. 
According to Undersea and Hyperbaric 
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Medical Society (UHMS), HBOT is an intervention in 
which a person breathes 100% oxygen intermittently 
inside a hyperbaric chamber at a pressure greater 
than sea level pressure (1 atmosphere absolute or 
ATA). Increased 1 ATA pressure is equivalent to a 
depth of 10 meters underwater. The therapeutic 
condition is achieved with a minimum pressure of 1.4 
ATA and breathes with 100% oxygen [12]. In general, 
DFUs therapy uses 100% oxygen and pressure 2-3 
ATA inside the hyperbaric chamber for 90 minutes per 
day [10], [13], [14]. 
The HBOT's mechanisms increase the tissue 
oxygen levels, decreased oedema, and kills anaerobic 
bacteria, resulting in the acceleration of wound 
healing [14]. Based on these mechanisms, many 
researchers use HBOT as one of the method 
therapies to DFUs [2], [6], [9], [13], [15].
 
HBOT is also 
able to improve the angiogenesis process, 
characterised by an increased in vascular endothelial 
growth factor (VEGF) levels. It can boost epithelial 
and granulation processes [13], [16], [17]. 
The wound or ulcer healing theory with 
angiogenesis mechanisms through the role of platelet-
derived growth factor (PDGF), transforming growth 
factor-beta (TGF-β), and vascular endothelial growth 
factor (VEGF) have been extensively studied in 
animals. However, the use of HBOT in DFUs patients, 
in HBOT’s role in increasing VEGF through the 
angiogenesis process has not been widely discussed 
[18]. Tumour necrosis factor-alpha (TNF-α) is certainly 
elevated in inflammation, but in DFUs patients who 
get HBOT has not been explained why HBOT can 
decrease TNF-α levels. Fundamentally, the role of 
HBOT heals wounds through oxidative stress and can 
suppress inflammatory reactions with decreased TNF-
α [19]. 
It is explained that in the DFUs healing 
process requires the study of the biomolecular role. 
Based on these theories, we were challenged to learn, 
understand, and explore more about the HBOT, not 
only in accelerating wound healing as a clinical 
feature, but also the changes in biomolecular that may 
help DFUs patients.  
This study aimed to demonstrate the HBOT 
role as a complementary therapy to provide more 
rapid clinical recovery through increased VEGF and 
decreased TNF-α in DFUs wound healing. 
 
 
Material and Methods 
 
This research is an experimental study using 
randomised pre and post-test control groups design, 
with permuted block to HBOT and control group. All 
patients received the same wound treatment. In the 
HBOT group, the patient got HBOT, but the control 
group did not. This research was conducted at 
Sanglah General Hospital, Denpasar, Bali, after 
obtaining the ethical clearance of research 
1582/UN.14.2/Litbang/2015 from Research Unit of 
Medical Faculty of Udayana University and Sanglah 
General Hospital. All subjects of this research were 
willing to follow the research by signing the agreement 
after getting the explanation (informed consent). 
Inclusion criteria were DM patients with DFU 
Wagner grade 3 and 4, aged 40-60 years, and TcPO2 
> 40 mmHg. TcPO2 measurement was performed at 
the proximal of the ulcerated foot. Exclusion criteria 
were DM patients with DFU Wagner 1, 2, and 5, 
patients with other organ abnormalities such as heart 
failure, pulmonary infections, pulmonary emphysema, 
pneumothorax, chronic obstructive pulmonary 
disease, liver disease or hepatitis, stroke, kidney 
failure, and sepsis or multiple organ failure. 
Before the debridement, serum sampling was 
performed to get a baseline value of VEGF and TNF-α 
biomarkers. Another laboratory test was taken, such 
as random blood sugar and serum albumin. Blood 
centrifugation was done at the velocity of 3000 rpm for 
10 minutes. Serum was inserted in the safe lock 
microcentrifuge tube and stored in a freezer at -20°C 
in the laboratory. Biomarker examination used 
quantitative sandwich enzyme immunoassay. VEGF 
test used the catalogue number PDVE00, and TNF-α 
used the catalogue number DTA00C. After 
debridement, the wounds were treated with normal 
saline, sterile gauze, and elastic bandage as standard 
management. 
The total sample was 32 patients, divided into 
two groups (HBOT and control), with 16 patients, 
respectively. In HBOT group, patients breathed 100% 
oxygen at 2.4 ATA in a multiplace hyperbaric chamber 
for 90 minutes each session per day, and five days in 
a week until 20th session (four weeks). At the end of 
therapy after four weeks from the surgical 
debridement, second serum sampling was performed 
again to check VEGF and TNF-α biomarkers in the 
same way as serum sampling at the beginning of the 
study. Epithelialization was also performed at the end 
of therapy. We measured the average of epithelial 
growth of the entire edges of the wound, in a circle, 
every 1 cm, from healthy skin to the edge of the ulcer. 
Data analysis was conducted by the IBM 
SPSS statistics version 23.0 for Windows (IBM 
Corporation). Descriptive analysis to described patient 
characteristics in both groups. We evaluated the 
normality of numerical data with the Shapiro-Wilk test. 
If the data were normally distributed, parametric test 
with paired T-test for pre and post-test data, and 
evaluation of value between groups with independent 
T-test. If numerical data were not normally distributed, 
data transformation with base-e logs was also known 
as natural logs (Ln), and it tested by the same test. If 
after transformation, the data was not normally 
distributed, then used the non-parametric test, such 
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as a paired T-test replaced with Wilcoxon test and 
independent T-test with Mann-Whitney U test. The 
further analysis used path analysis with Stata 12.0 
(StataCorp). Significant test was p-value < 0.05. 
 
 
Results 
 
The subjects collected in this study were 32 
DM patients with DFUs Wagner 3-4 (Table 1), with 
average age 52 years old, duration of DM 6 years, 
and body mass index (BMI) around 23 kg/m
2 
(normal 
limit). In the control group, patients had foot ulcers 
longer, slightly higher TcPO2, higher random blood 
sugar, and lower albumin serum than HBOT group. 
Both groups were comparable with p-value > 0.05. 
Table 1: Characteristics of patients before treatment 
 HBOT 
(n = 16) 
Control 
(n = 16) 
p value 
Age (years)
a
 52.56 ± 5.81 52.75 ± 5.17 0.924
b
 
DFUs duration (weeks)
a
 5.75 ± 4.19 7.53 ± 12.98 0.779
c
 
DM duration (years)
a
 6.33 ± 6.81 6.75 ± 6.16 0.319
c
 
BMI (kg/m
2
) 23.43 ± 3.86 23.99 ± 4.23 0.687
c
 
TcPO2 (mmHg)
a
 58.11 ± 4.87 59.18 ± 12.94 0.759
b
 
Random blood sugar (mg/dl)
a
 238.00 ± 106.55 266.50 ± 122.40 0.488
b
 
Albumin serum (mg/dl)
a
 3.08 ± 0.75 2.92 ± 0.55 0.692
d
 
Sex (%)    
Male 8 (50) 5 (31.25) 0.280
e
 
Female 8 (50) 11 (68.75)  
a
Mean ± standard deviation; 
i
ndependent T-test; 
c
Ln Independent T-test; 
d
Mann-Whitney U 
test; 
e
Chi-square test. 
 
Table 2 showed average VEGF levels at 
baseline was similar 151 pg/ml in both groups, but 
after four weeks therapy there was significant 
escalation of VEGF in HBOT group than control group 
(277.42 ± 171.75 pg/ml, 95% CI 185.90-368.94 pg/ml 
vs 169.21 ± 78.92 pg/ml, 95% CI 127.16-211.26 
pg/ml, respectively, p = 0.013). We showed pre and 
post-test VEGF levels in HBOT was different 
significant p < 0.001 with escalation value of 125.75 ± 
116.76 pg/ml, but in control group was a slight 
escalation of 17.94 ± 81.26 pg/ml, p = 0.439. The 
escalation value (effect size) between HBOT and 
control groups was a significant difference, p = 0.005. 
Table 2: VEGF levels between groups 
VEGF (pg/ml) HBOT Control p-value 
Baseline 151.67 ± 96.46 151.27 ± 51.98 0.501
b
 
After therapy 277.42 ± 171.75 169.21 ± 78.92 0.013
b
 
p value < 0.001
a
 0.439
a
  
All value in mean ± standard deviation; 
a
Ln Dependent T test; 
b
Ln Independent T test. 
 
We analysed TNF-α levels between groups in 
Table 3. It showed similar value at baseline (p = 0.91), 
but TNF-α levels at four weeks therapy was 
significantly different between groups (p = 0.01), in 
HBOT group was 28.51 ± 4.25 pg/ml, 95%CI 26.24-
30.77 pg/ml, and in control group was 35.33 ± 13.82 
pg/ml, 95%CI 27.96-42.69 pg/ml. TNF-α levels in 
HBOT group was reduction 4.43 ± 5.03 pg/ml, but in 
control group was escalation 1.94 ± 10.72 pg/ml (p = 
0.02). There was a significant reduction of TNF-α 
levels in the HBOT group (p = 0.005). 
Table 3: TNF-α levels between groups 
TNF-α (pg/ml) HBOT Control p-value 
Baseline 32.93 ± 4.43 33.38 ± 5.29 0.91
b
 
After therapy 28.51 ± 4.25 35.33 ± 13.82 0.01
b
 
p value 0.005
a
 0.814
a
  
All value in mean ± standard deviation; 
a
Wilcoxon test; 
b
Mann-Whitney U test. 
 
Besides the biomolecular analysis, we 
measured the epithelialization of ulcers at the end of 
therapy. There was faster epithelialization in HBOT 
group than the control group (3.81 ± 1.38 mm, 95%CL 
3.07-4.54 mm vs 1.27 ± 0.61 mm, 95%CI 0.95-1.60 
mm, respectively, p < 0.001). We also performed path 
analysis to evaluate the relationship between HBOT, 
VEGF, and TNF-α to epithelialization (Figure 1). The 
relationship that occurs as a direct and indirect effect 
on epithelialization. Directly, the HBOT had a 
significant effect on the epithelialization (p < 0.001). 
But indirectly, HBOT affected epithelialization through 
the escalation of VEGF levels and reduction of TNF-α 
levels. However, the most important role of 
epithelialization was VEGF levels (p = 0.042). 
 
Figure 1: Diagram of path analysis of HBOT to VEGF, TNF-α, and 
epithelialisation. Note: *p <0.05. - HBOT did not significantly 
escalate VEGF by 47.35%, p = 1.00; - HBOT did not significantly 
reduce TNF-α by 35.46%, p = 1.00; - HBOT significantly escalated 
epithelialization by 61.02%, p <0.001; - VEGF did not significantly 
escalate TNF-α by 7.52%, p = 1.00; - VEGF significantly escalated 
epithelialization by 24.13%, p = 0.042; - TNF-α did not significantly 
escalate VEGF by 26.96%, p = 1.00; - TNF-α did not significantly 
reduce epithelialization by 22.14%, p = 0.054 
 
 
Discussion 
 
Hyperbaric oxygen therapy is tailored made 
for each disease. The frequency of HBOT varies from 
three to five sessions for acute cases [13], [20]. Ten to 
twenty HBOT sessions for DFU [2], [6], [9], [10], even 
fifty to sixty times for chronic cases and slow healing 
wound [13], [20]. The 5-10 HBOT sessions or less 
than 20 sessions on DFUs gives no clinical results 
maximum. The 30 HBOT sessions or more 20 
sessions gives the same result with 20 HBOT 
sessions. Therefore, we use 20 sessions of 100% 
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oxygen and 2.4 ATA in a multiplaced hyperbaric room, 
one session for 90 minutes intermittent (every 30 
minutes, patients resting 5 minutes), one session per 
day, and five sessions per week [2], [9], [10], [13], 
[14]. For this study indicated for type 2 DM with DFU 
Wagner 3-4. 
In this study VEGF levels can be seen in 
Table 2, that the control group VEGF levels increased, 
but not statistically significant (p = 0.439), while the 
HBOT group experienced a very significant increase 
(p < 0.001). The increase in VEGF in the HBOT group 
was higher than the control group with significant 
difference (p = 0.005). 
In the Asano et al., Study [21] using mice, 
ligated left femoral artery and given HBOT found 
VEGF mRNA increased, at 24 hours and 72 hours, 
but returned to normal after day 14. Increased VEGF 
mRNA is due to ischemia process. In contrast to 
bFGF (basic fibroblast growth factor) and HGF 
(hepatocyte growth factor) which at 24 and 72 hours 
also increased, but greatly improved on day 14 after 
administration of HBOT. This indicates that VEGF 
mRNA is elevated because it is induced by ischemia 
alone. Yuan et al., Study [22] obtaining VEGF did not 
increase in the administration of HBOT. The early 
increasing of VEGF, occurs due to lactate and 
increased NO (nitric oxide) and not due to hyperoxia 
in HBOT. 
In the Al Waili et al., Study [23] found that 
VEGF levels increased significantly after HBOT 
administration, while PGE2 (prostaglandin E2) and 
Cox-2 (cyclooxygenase-2) mRNA values decreased. It 
was concluded that cytokines, prostaglandins, and NO 
probably induced by increased VEGF levels. VEGF 
plays an important role in liver regeneration, and the 
effects of VEGF are mediated through two tyrosine 
kinase receptors [24]. Different oxygen pressures will 
lead to activation of signalling pathway differences 
that stimulate VEGF expression to angiogenesis. 
Hyperoxia causes ROS (reactive oxygen species) 
production that affects HIF-1 (hypoxia-inducible factor-
1) and causes VEGF expression [25]. 
The increase of VEGF levels in the HBOT 
group was greater and significantly higher than the 
control group; this represents that HBOT may activate 
angiogenesis through increasing VEGF levels. 
According to Thom [19], HBOT can increase the 
reactive oxygen compound, will synthesise more 
growth factors through increased SDF-1 (stromal-
derived factor-1) ingredients, angiopoietin, FGF, TGF-
β1, and VEGF through HIF-1. From these 
components, it is the improvement of 
neovascularisation. The ROS or RNS (reactive 
nitrogen species) compound affects the cell, in which 
the PKC (protein kinase C) is activated and various 
gene expression occurs such as endothelin-1, VEGF, 
TGF-β, PAI-1 (plasminogen activator inhibitor-1), NF-
κB, NAD(P)H oxidase, and decreased eNOS 
(endothelial nitric oxide synthase) [26]. 
Wound healing factors in DFUs depend on 
growth factor, angiogenic response, macrophage 
function, collagen accumulation, the barrier function of 
the epidermal cell, keratocyte granulation quality, 
fibroblast migration, epidermal nerve proliferation, 
bone healing, ECM (extracellular matrix) 
accumulation, and remodelling of MMPs (matrix 
metalloproteinases) [27]. 
The most important growth factor in the 
angiogenesis process is VEGF. VEGF of 17-23 kDa 
can stimulate proliferation and endothelial cell 
migration. VEGF-A is believed to be responsible for 
fatty tissue angiogenesis [28]. VEGF-B (21 kDa) of 
43% is identical to VEGF-A 165. It also stimulates 
angiogenesis and has implications of ECM 
degradation through plasminogen activation regulation 
[29]. VEGF-C (23 kDa) showed 35% homologous with 
VEGF-A 165, which play an important role in 
angiogenesis and lymphangiogenesis [30], [31]. 
VEGF-D (22 kDa) of 48% identical to VEGF-C also 
promotes the growth of lymphatic channels [32]. 
The TNF-α levels changes in our study, 
shown in Table 3. There was no significant increase in 
TNF-α levels (p = 0.814). In the HBOT group, there 
was a significant decrease in TNF-α levels (p = 0.005) 
after treatment. TNF-α levels after four weeks were 
significantly different between the control group and 
the HBOT group (p = 0.01). The difference of TNF-α 
levels between the initial treatment and after four 
weeks was significantly different (p = 0.02). 
This condition was described by Thom [19], 
that hyperbaric oxygen therapy increases oxygen 
levels in the cell, resulting in the formation of reactive 
oxygen compounds or reactive nitrogen compounds 
(ROS or RNS). These reactive compounds will 
increase at hyperoxia state. Reactive oxygen 
compounds will suppress monocyte cells and reduce 
the synthesis of chemokines. The small number of 
monocytes and low level of chemokines will decrease 
the amount of cytokine production such as TNF-α. 
Thus, HBOT decreases the overall inflammatory 
response. In vivo, TNF-α is a major regulator of 
inflammatory immune responses, both locally and 
systemically. There are homologous genes from TNF, 
such as TNF-α and lymphotoxin (TNF-ß). These 
genes are present on the short arm of chromosome 6 
[33]. A systemic inflammatory response will decrease 
the synthesis of various cytokines, including a 
decrease in TNF-α levels. Besides, the decrease of 
TNF-α may be induced by the HIF-1 effect mechanism 
[19]. TNF-α is a molecule formed by activated 
mononuclear phagocytes, including endothelial cells 
and fibroblast cells. In hyperglycaemia, increased 
ROS level may induce the release of TNF-α, IL-1, and 
IL-6 through the NF-κB pathway [34]. While on the 
administration of HBOT, this condition will not happen 
[19]. 
Excessive formation of ROS or RNS will be 
followed by the formation of an oxidant as a 
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scavenger, that will counter the overproduction of 
ROS. There are two kinds of antioxidants, such as 
enzymatic (superoxide dismutase, catalase, 
thioredoxin-glutathione dependent peroxidase, and 
reductase) and non-enzymatic (vitamin C, vitamin E, 
thioredoxin, glutathione, uric acid, β carotene, and 
carotene). These antioxidants are adequate to fight 
against oxidants. The decrease of TNF-α in the HBOT 
adjuvant therapy, depending on duration, frequency is 
given HBOT, and HBOT dose per session. 
Administration of HBOT 3 ATA for one-hour at 
massive bleeding decreased TNF-α compared to 
control. One-hour 100% oxygen delivery with 2.8 ATA 
also inhibits elevated TNF-α in ischemia-reperfusion 
injury of intestinal [35], [36]. Clinical judgement of 
DFUs was done by observation and measurement of 
epithelial width growth, from the margin of healthy skin 
into the wound, measured after four weeks of 
treatment. The control group, the epithelial growth of 
DFUs, was 1.27 ± 0.61 mm. The HBOT group, the 
epithelial growth of the patient, was 3.81 ± 1.38 mm. 
There was a significant difference in both groups' 
epithelial growth. Epithelial growth in the HBOT group 
was much better than the control group (p < 0.001). 
In acute lesions, the epithelial growth of 
normal skin cells is 0.1 mm per day or 0.75 mm per 
week and 3 cm during the proliferative phase [37], 
whereas in chronic wounds, the epithelial growth 
slows down. In a chronic condition, the network 
healing process fails to achieve functional and 
anatomy integrity as in normal condition. Various 
factors that cause chronic wounds are still not fully 
understood, but one of the most important factors is 
the occurrence of oxygen deficiency resulting in 
prolonged tissue hypoxia. The ECM deposit also 
becomes less due to the production of fibroblasts and 
collagen remodelling highly dependent on the 
adequacy of tissue oxygen. In the development of 
chronic wounds, the healing process can be stopped 
at every phase, especially in the inflammatory or 
proliferative stage. Inhibition of the proliferative phase 
causes the build-up of neutrophil production in tissues 
that would otherwise destroy growth factors and 
degrade ECM components. This causes the tissue to 
become fragile [38]. In diabetes, the persistent 
inflammatory phase leads to prolonged maturation 
time of the granulation tissue and the parallel 
reduction of tensile strength [39]. In acute healing, 
there will be a gradual wound healing process based 
on the hemostasis phase, the inflammatory phase, the 
proliferation phase, and the remodelling phase. While 
in chronic wounds, the inflammatory phase 
persistently occurs [40]. 
Based on the description above, we can 
assemble the role of each molecule or compound in 
the cell or body to physiologically wound healing 
process and progression [41]. HBOT role as adjuvant 
therapy may activate the system to accelerate the 
DFUs healing process. According to Mendes et al., 
[41] several molecules and compounds take a big role 
in DFUs healing process, including genetic changes. It 
is an endless orchestra of harmony; there are many 
things that have not been revealed and fully 
understood. HBOT offers a variety of beneficial 
effects. In this study that HBOT can be used for the 
treatment of DFUs because HBOT causes a change 
in pathobiology, such as increased VEGF in the 
plasma will stimulate angiogenesis and 
neovascularisation. A decrease of TNF-α as a sign of 
reduced inflammatory reactions and improvement of 
immunity in plasma, followed by increased granulation 
as fibroblast work undergoes proliferation and 
migration. The clinical improvement of epithelial 
acceleration in adjuvant HBOT proved that HBOT 
improves ulcer healing through various growth factors, 
cell proliferation and migration, increased vascular 
permeability through vasoconstriction mechanisms, 
and improves vascular endothelial function. 
The role of HBOT to VEGF, TNF-α and 
epithelial growth can be seen in the path analysis 
(Figure 1). By path analysis, the relationship was 
HBOT directly affecting epithelialization significantly (p 
< 0.001). HBOT indirectly affects epithelialization via 
VEGF and TNF-α. However, the most important role 
in the indirect relationship between HBOT and 
epithelialisation was VEGF (p = 0.042). According to 
Mendes et al., [41] in the wound healing process, 
many things are involved and influential. Molecules 
and compounds take their roles, genetic change of 
chain, interrelated, and dependent. But Yuan et al., 
Study [22] obtaining VEGF did not increase in the 
administration of HBOT. 
In conclusion, HBOT administration leads to 
increased VEGF, decreased TNF-α, and accelerated 
wound healing of DFUs patients. Clinical efficacy in 
humans reported by previous investigators can be 
demonstrated through this biomolecular study. The 
biomolecular findings reinforce the theoretical basis, 
helping to explain human clinical findings, and adding 
biomolecular research to animals thus adding to the 
validity of previous studies. HBOT directly affects 
epithelialization, but also induces indirectly through 
VEGF enhancement mechanism and decreases TNF-
α. However, the most important role in indirect 
epithelialization process is VEGF. 
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